Connect the Dots

Organization

Genovo

Biotechnology company founded by James Wilson that financed research at the University of Pennsylvania's Institute for Human Gene Therapy and held the rights to license patents from his lab.

5 links, 0 backed by primary records

Play the story Explore connections

Connections 5

founded by

  • James M. Wilson 1992 Scholarship & press 12

    He denied in 1999 that money drove his research and said the financial relationship was fully explained on the consent form.

stakeholders

  • James M. Wilson Scholarship & press 23

    A Harvard course case study, citing Robert Steinbrook (2008) and the Wall Street Journal of 10 August 2000, says Wilson and his family held 30 percent, non-voting. We could not open either source. A 2017 scholarly article says only that he was allowed to control up to 30 percent of the stock. No relative is named in any source we read.

  • University of Pennsylvania Scholarship & press 24

    A scholarly article says that in 1995 Penn waived part of its conflict-of-interest guidelines, which had given Genovo exclusive rights to license patents from Wilson's lab. A Harvard course case study says Penn's conflict committee reviewed his ties in 1994 and did not seek to end them. Penn denied that money played any part in the trial.

funded

  • University of Pennsylvania Scholarship & press 245

    Sources differ on the money: more than $4 million over five years (Daily Pennsylvanian, 2000), more than $4 million a year (a Harvard course case study), nearly a quarter of the institute's budget (a scholarly article).

involved in

Timeline 1 date
  1. 1992 James M. Wilson founded Genovo
Proof 5 sources
  1. Gene study at Penn under fire, The Daily Pennsylvanian, Nov 1999. Scholarship & press
    Wilson founded a private gene-therapy company called Genovo in 1992
  2. Ethical Considerations in Phase I studies: Gelsinger Case, HarvardX (Harvard T.H. Chan School of Public Health), course case study. Scholarship & press
    Prior to his move to UPenn, Dr. Wilson had founded Genovo Inc., which had the rights to market his discoveries related to gene transfer
    Dr. Wilson and his family had a 30% nonvoting equity stake in Genovo
    UPenn had a 3.2% equity stake
    By 1999, Genovo had provided more than $4 million a year to the Institute.
    Please be aware that Dr. James M. Wilson and Genovo Inc. have a financial interest in a successful outcome from the research involved in this study.
  3. Death but one unintended consequence of gene-therapy trial, CMAJ, 2001. Scholarship & press
    Wilson, director of the Penn institute where Gelsinger was treated, owned stock in a company, Genovo, that provided financing for the institute.
  4. Penn hit by gene therapy lawsuit, The Daily Pennsylvanian, 19 Sep 2000. Scholarship & press
    The University was given shares of the company
    By 1999, Genovo had agreed to fund the IHGT’s research, giving them more than $4 million over five years to conduct genetic research.
  5. Legislative Issues in Disclosing Financial Conflicts of Interest to Participants in Biomedical Research: Effectiveness and Methodology, Journal of Korean Medical Science, 2017. Scholarship & press
    Genovo “provide(d) nearly a quarter of the budget” to the IHGT
Page history 1 change
  1. Add 55 stories, each checked against its sourcesAlibek96e92fe6

Something wrong or missing? Tell us, with a source, or edit this page.